Logo
NEXFILL Volume (1ml with Lidocaine)

NEXFILL Volume (1ml with Lidocaine)

Nexfill

Dermal fillers
  • CE Marked monophasic hyaluronic acid dermal filler with lidocaine, certified via an EU Notified Body and EU representative based in Germany.
  • Manufactured in accordance with international medical device quality standards for injectable HA fillers, including strict controls on residual BDDE, endotoxins and protein impurities.
  • Utilises EDQM Approved hyaluronic acid raw material for medical use, as referenced in Nexfill’s certification information.
  • Subject to distributor compliance requirements in CE Recognising regions, including EU and UK markets, where applicable.
Monophasic cross-linked hyaluronic acid dermal filler for facial volumizing and contouring (Volume line, 1 mL with lidocaine)

Description

NEXFILL Volume (1ml with Lidocaine) is a high-density, monophasic hyaluronic acid dermal filler designed to restore facial volume, enhance contours and smooth deep wrinkles for a plump, youthful appearance. Formulated with 24 mg/ml HA and 0.3% lidocaine, it delivers deep hydration, stimulates collagen production and provides long-lasting, natural-looking results with significantly reduced swelling due to its ultra-pure gel and approximately 60% lower BDDE content compared with many conventional fillers.

Bnefits

  • Restores lost facial volume and enhances overall facial contours.
  • Smooths deep wrinkles and folds, including nasolabial folds.
  • Monophasic HA gel provides deep, long-lasting hydration and a radiant, healthy skin glow.
  • Uses approximately 60% less BDDE cross-linking agent than many traditional fillers, resulting in a purer formula and significantly less post-treatment swelling.
  • Promotes fibroblast activity and collagen production, helping to improve skin elasticity and quality over time.
  • High viscoelasticity and cohesive gel for stable, long-lasting volumizing and sculpting.
  • Contains lidocaine (numbing agent) for increased patient comfort during injection.
  • CE-marked filler manufactured under stringent medical device quality and purity standards.
  • Easily moldable and reversible with hyaluronidase if required.

Indications

  • Facial contour enhancement and volumizing.
  • Chin augmentation and contouring.
  • Nasolabial folds (moderate to severe).
  • Cheekbone and mid-face volumizing.
  • Mandibular angle and jawline contouring.
  • Profile balancing (non-surgical profileplasty) where appropriate.
  • Correction of deeper wrinkles and folds in areas approved in the Instructions for Use.

Composition

  • Hyaluronic Acid 24 mg/ml (cross-linked, non-animal origin).
  • Lidocaine 0.3% (amide-type local anaesthetic).
  • BDDE (1,4-butanediol diglycidyl ether) as cross-linking agent; residual non-crosslinked BDDE is reduced to below the analytical detection limit according to manufacturer purification data.
  • Endotoxin and protein residues are minimized through extensive purification to ultra-low impurity levels in line with Nexfill technology specifications.

Formulation

  • Monophasic, cross-linked hyaluronic acid gel with lidocaine (Volume line, 24 mg/ml HA + 0.3% lidocaine).
  • High-density, high-viscoelasticity gel developed for volumizing and contouring of the face.
  • Ultra High Density (UHD) / high-density tapping technology combining chemical and mechanical cross-linking for homogeneous gel structure.
  • Smooth, cohesive gel designed for gradual, even distribution and natural-looking results with minimal puffiness.
  • Ultra-low residual impurities (BDDE, endotoxins and proteins) due to multi-stage purification.

Packaging

  • Box containing 1 x 1 mL pre-filled sterile syringe of Nexfill Volume (with lidocaine).
  • Each syringe supplied sterile in blister packaging; needles or cannulas may be included depending on market and distributor – refer to local pack contents.
  • Some wholesalers offer commercial quantity options such as single units and multi-box bundles for clinic use.

Usage

  • For use only by suitably trained, qualified and appropriately insured medical/aesthetic professionals, in accordance with local laws and professional guidelines.
  • Intended for injection into the mid to deep dermis and/or subcutaneous plane depending on indication (e.g., chin, jawline, cheekbone, nasolabial folds); practitioners should follow the official Nexfill Instructions for Use (IFU) and their clinical training when selecting depth and technique.
  • Inspect packaging, blister and syringe before use; do not use if packaging is damaged, opened or if the gel shows discoloration or visible particles.
  • Use strict aseptic technique throughout preparation and injection. Disinfect the treatment area thoroughly before injection.
  • Inject slowly using low, controlled pressure, aspirating according to the practitioner’s protocol to reduce risk of intravascular injection.
  • Avoid overcorrection; allow for initial swelling when judging the correction and sculpting results.
  • After treatment, advise the patient to avoid intense heat (saunas, steam rooms, sunbeds), strenuous exercise, and alcohol for an appropriate period, and to avoid touching or massaging the area unless instructed.
  • Monitor the patient for early signs of vascular compromise or other adverse events and be prepared to manage complications, including having hyaluronidase and emergency equipment available according to clinic protocols.
  • Dispose of all used syringes, needles, cannulas and associated materials as clinical sharps waste. Do not resterilise or reuse single-use components.
  • Always consult the latest official Nexfill IFU and local clinical guidelines for complete directions for use, indications, contraindications and precautions.

Contraindications

  • Hypersensitivity or allergy to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or to any of the excipients.
  • History of severe anaphylactic reactions or multiple severe allergies.
  • Presence of active skin inflammation, infection, acne, dermatitis or herpetic lesions at or near the intended injection site.
  • Patients with uncontrolled systemic disease, significant bleeding disorders or those on anticoagulant/antiplatelet therapy where the risk cannot be adequately managed.
  • Autoimmune disorders or immunocompromised states unless, in the clinician’s judgement, benefits clearly outweigh risks and close monitoring is undertaken.
  • Pregnant or breastfeeding women, due to insufficient safety data.
  • Patients under 18 years of age.
  • Previous permanent or non-hyaluronic acid fillers in the planned treatment area unless managed by highly experienced injectors with appropriate risk assessment.
  • Any other contraindications and limitations specified in the latest official Nexfill Instructions for Use.

Adverse Effects

  • Typical transient injection-site reactions such as redness (erythema), swelling, tenderness or pain, bruising, itching, firmness or small lumps/bumps.
  • Local oedema, induration, palpable nodules or unevenness in the treated area.
  • Temporary changes in skin colour (hyperpigmentation or hypopigmentation) around injection sites.
  • Bleeding or haematoma at the injection site.
  • Local infection, including possible abscess formation in rare cases.
  • Hypersensitivity reactions, including immediate or delayed-onset allergic reactions.
  • Granuloma formation or chronic inflammatory nodules.
  • Very rare but serious complications related to inadvertent intravascular injection, such as vascular occlusion, skin ischaemia or necrosis, and visual disturbances including vision changes or blindness when injecting in high-risk areas.
  • Any additional risks, warnings and possible adverse events described in the official Nexfill IFU should be carefully reviewed with the patient as part of informed consent.

Storage Conditions

  • Store at a controlled room temperature typically between 2°C and 25°C, as stated on the packaging; do not freeze.
  • Keep away from direct sunlight and heat sources.
  • Store in the original blister and outer carton to maintain sterility and protect the product from light and physical damage.
  • Do not use after the expiry date printed on the packaging.
  • Do not use the product if it has been improperly stored (e.g., exposed to extreme temperatures) or if any visible defects in the syringe, blister or gel are observed.

Duration

Results are typically long-lasting, with clinical effect often maintained for up to approximately 12 months in most facial volumizing and contouring indications, depending on area treated, injection technique, product volume used and individual patient factors such as metabolism and lifestyle.

Onset

Visible volumizing, contouring and wrinkle-smoothing effects are generally immediate following injection, with the final aesthetic outcome becoming apparent after initial post-injection swelling and redness have subsided over the following days.

Browse more Dermal fillers

Top Treatments

Top Cities in the UK